Search

Your search keyword '"Renae Quale"' showing total 19 results
Start Over Author "Renae Quale" Search Limiters Full Text
19 results on '"Renae Quale"'

1. Supplemental Figure SF-11 from Outcome-Related Signatures Identified by Whole Transcriptome Sequencing of Resectable Stage III/IV Melanoma Evaluated after Starting Hu14.18-IL2

Author

Paul M. Sondel, Javed Khan, Mark R. Albertini, KyungMann Kim, Renae Quale, Zachary S. Morris, Amy K. Erbe, Cindy Zuleger, Jacquelyn A. Hank, Viharkumar Patel, Young K. Song, Vineela Gangalapudi, Berkley E. Gryder, Sivasish Sindiri, Jun S. Wei, Erik A. Ranheim, Igor B. Kuznetsov, and Richard K. Yang

Abstract

Expression of Many Interleukins (IL) Prognosticates Favorable Survival in Group A and Group B

Published
2023

2. Supplemental Figure SF-16 from Outcome-Related Signatures Identified by Whole Transcriptome Sequencing of Resectable Stage III/IV Melanoma Evaluated after Starting Hu14.18-IL2

Author

Paul M. Sondel, Javed Khan, Mark R. Albertini, KyungMann Kim, Renae Quale, Zachary S. Morris, Amy K. Erbe, Cindy Zuleger, Jacquelyn A. Hank, Viharkumar Patel, Young K. Song, Vineela Gangalapudi, Berkley E. Gryder, Sivasish Sindiri, Jun S. Wei, Erik A. Ranheim, Igor B. Kuznetsov, and Richard K. Yang

Abstract

Network-level analysis of genes correlated with the overall survival (OS) time in Group A indicates that ELAVL1 is a hub protein that interacts with the products of many of these genes.

Published
2023

3. Supplemental Figure SF-12 from Outcome-Related Signatures Identified by Whole Transcriptome Sequencing of Resectable Stage III/IV Melanoma Evaluated after Starting Hu14.18-IL2

Author

Paul M. Sondel, Javed Khan, Mark R. Albertini, KyungMann Kim, Renae Quale, Zachary S. Morris, Amy K. Erbe, Cindy Zuleger, Jacquelyn A. Hank, Viharkumar Patel, Young K. Song, Vineela Gangalapudi, Berkley E. Gryder, Sivasish Sindiri, Jun S. Wei, Erik A. Ranheim, Igor B. Kuznetsov, and Richard K. Yang

Abstract

Some Cluster of Differentiation Expression Prognosticates Favorable Survival in Group A and Group B

Published
2023

4. Supplemental Figure SF-05 from Outcome-Related Signatures Identified by Whole Transcriptome Sequencing of Resectable Stage III/IV Melanoma Evaluated after Starting Hu14.18-IL2

Author

Paul M. Sondel, Javed Khan, Mark R. Albertini, KyungMann Kim, Renae Quale, Zachary S. Morris, Amy K. Erbe, Cindy Zuleger, Jacquelyn A. Hank, Viharkumar Patel, Young K. Song, Vineela Gangalapudi, Berkley E. Gryder, Sivasish Sindiri, Jun S. Wei, Erik A. Ranheim, Igor B. Kuznetsov, and Richard K. Yang

Abstract

The Majority of Immunologic Gene Signatures Significantly Predict RFS and OS in Group A, but not in Group B.

Published
2023

5. Supplemental Figure SF-01 from Outcome-Related Signatures Identified by Whole Transcriptome Sequencing of Resectable Stage III/IV Melanoma Evaluated after Starting Hu14.18-IL2

Author

Paul M. Sondel, Javed Khan, Mark R. Albertini, KyungMann Kim, Renae Quale, Zachary S. Morris, Amy K. Erbe, Cindy Zuleger, Jacquelyn A. Hank, Viharkumar Patel, Young K. Song, Vineela Gangalapudi, Berkley E. Gryder, Sivasish Sindiri, Jun S. Wei, Erik A. Ranheim, Igor B. Kuznetsov, and Richard K. Yang

Abstract

Treatment Schema.

Published
2023

6. Supplemental Figure SF-15 from Outcome-Related Signatures Identified by Whole Transcriptome Sequencing of Resectable Stage III/IV Melanoma Evaluated after Starting Hu14.18-IL2

Author

Paul M. Sondel, Javed Khan, Mark R. Albertini, KyungMann Kim, Renae Quale, Zachary S. Morris, Amy K. Erbe, Cindy Zuleger, Jacquelyn A. Hank, Viharkumar Patel, Young K. Song, Vineela Gangalapudi, Berkley E. Gryder, Sivasish Sindiri, Jun S. Wei, Erik A. Ranheim, Igor B. Kuznetsov, and Richard K. Yang

Abstract

Expanded Pathway-Level Enrichment Analysis of Gene Sets Whose Expression Correlates with Overall Survival in Group A Patients

Published
2023

7. Supplemental Figure SF-04 from Outcome-Related Signatures Identified by Whole Transcriptome Sequencing of Resectable Stage III/IV Melanoma Evaluated after Starting Hu14.18-IL2

Author

Paul M. Sondel, Javed Khan, Mark R. Albertini, KyungMann Kim, Renae Quale, Zachary S. Morris, Amy K. Erbe, Cindy Zuleger, Jacquelyn A. Hank, Viharkumar Patel, Young K. Song, Vineela Gangalapudi, Berkley E. Gryder, Sivasish Sindiri, Jun S. Wei, Erik A. Ranheim, Igor B. Kuznetsov, and Richard K. Yang

Abstract

Hu14.18-IL2 Treatment Improves Direct Positive Correlations between Myeloid and Lymphoid Cells as indicated by ssGSEA Signatures

Published
2023

8. Supplemental Figure SF-09 from Outcome-Related Signatures Identified by Whole Transcriptome Sequencing of Resectable Stage III/IV Melanoma Evaluated after Starting Hu14.18-IL2

Author

Paul M. Sondel, Javed Khan, Mark R. Albertini, KyungMann Kim, Renae Quale, Zachary S. Morris, Amy K. Erbe, Cindy Zuleger, Jacquelyn A. Hank, Viharkumar Patel, Young K. Song, Vineela Gangalapudi, Berkley E. Gryder, Sivasish Sindiri, Jun S. Wei, Erik A. Ranheim, Igor B. Kuznetsov, and Richard K. Yang

Abstract

Some FcR Expression Prognosticates Favorable Survival in Group A, But Not Group B

Published
2023

9. Supplemental Figure SF-06 from Outcome-Related Signatures Identified by Whole Transcriptome Sequencing of Resectable Stage III/IV Melanoma Evaluated after Starting Hu14.18-IL2

Author

Paul M. Sondel, Javed Khan, Mark R. Albertini, KyungMann Kim, Renae Quale, Zachary S. Morris, Amy K. Erbe, Cindy Zuleger, Jacquelyn A. Hank, Viharkumar Patel, Young K. Song, Vineela Gangalapudi, Berkley E. Gryder, Sivasish Sindiri, Jun S. Wei, Erik A. Ranheim, Igor B. Kuznetsov, and Richard K. Yang

Abstract

Expression of Immunologic Genes Significantly Predict RFS and OS in Group A, but not in Group B.

Published
2023

10. All Supplemental Tables from Outcome-Related Signatures Identified by Whole Transcriptome Sequencing of Resectable Stage III/IV Melanoma Evaluated after Starting Hu14.18-IL2

Author

Paul M. Sondel, Javed Khan, Mark R. Albertini, KyungMann Kim, Renae Quale, Zachary S. Morris, Amy K. Erbe, Cindy Zuleger, Jacquelyn A. Hank, Viharkumar Patel, Young K. Song, Vineela Gangalapudi, Berkley E. Gryder, Sivasish Sindiri, Jun S. Wei, Erik A. Ranheim, Igor B. Kuznetsov, and Richard K. Yang

Abstract

Supplemental Tables ST1 to ST14

Published
2023

11. Supplemental Figure SF-13 from Outcome-Related Signatures Identified by Whole Transcriptome Sequencing of Resectable Stage III/IV Melanoma Evaluated after Starting Hu14.18-IL2

Author

Paul M. Sondel, Javed Khan, Mark R. Albertini, KyungMann Kim, Renae Quale, Zachary S. Morris, Amy K. Erbe, Cindy Zuleger, Jacquelyn A. Hank, Viharkumar Patel, Young K. Song, Vineela Gangalapudi, Berkley E. Gryder, Sivasish Sindiri, Jun S. Wei, Erik A. Ranheim, Igor B. Kuznetsov, and Richard K. Yang

Abstract

Expression of Melanoma Marker Genes Portends Unfavorable RFS and OS in Group A but not Group B. Expression of Apoptotic Marker Genes Portends Favorable RFS and OS in Group A but not Group B.

Published
2023

12. Supplemental Methods and Figure Legends from Outcome-Related Signatures Identified by Whole Transcriptome Sequencing of Resectable Stage III/IV Melanoma Evaluated after Starting Hu14.18-IL2

Author

Paul M. Sondel, Javed Khan, Mark R. Albertini, KyungMann Kim, Renae Quale, Zachary S. Morris, Amy K. Erbe, Cindy Zuleger, Jacquelyn A. Hank, Viharkumar Patel, Young K. Song, Vineela Gangalapudi, Berkley E. Gryder, Sivasish Sindiri, Jun S. Wei, Erik A. Ranheim, Igor B. Kuznetsov, and Richard K. Yang

Abstract

Supplemental Methods and Figure Legends

Published
2023

13. Supplemental Figure SF-10 from Outcome-Related Signatures Identified by Whole Transcriptome Sequencing of Resectable Stage III/IV Melanoma Evaluated after Starting Hu14.18-IL2

Author

Paul M. Sondel, Javed Khan, Mark R. Albertini, KyungMann Kim, Renae Quale, Zachary S. Morris, Amy K. Erbe, Cindy Zuleger, Jacquelyn A. Hank, Viharkumar Patel, Young K. Song, Vineela Gangalapudi, Berkley E. Gryder, Sivasish Sindiri, Jun S. Wei, Erik A. Ranheim, Igor B. Kuznetsov, and Richard K. Yang

Abstract

Some TNF Family Expression Prognosticates Favorable Survival in Group A, But Not Group B

Published
2023

14. Supplemental Figure SF-08 from Outcome-Related Signatures Identified by Whole Transcriptome Sequencing of Resectable Stage III/IV Melanoma Evaluated after Starting Hu14.18-IL2

Author

Paul M. Sondel, Javed Khan, Mark R. Albertini, KyungMann Kim, Renae Quale, Zachary S. Morris, Amy K. Erbe, Cindy Zuleger, Jacquelyn A. Hank, Viharkumar Patel, Young K. Song, Vineela Gangalapudi, Berkley E. Gryder, Sivasish Sindiri, Jun S. Wei, Erik A. Ranheim, Igor B. Kuznetsov, and Richard K. Yang

Abstract

Killer Immunoglobulin-Like Receptors (KIRs) and Killer Cell Lectin-Like Receptors (KLRs) Prognosticate Favorable Survival in Group A, But Not Group B

Published
2023

15. Data from Outcome-Related Signatures Identified by Whole Transcriptome Sequencing of Resectable Stage III/IV Melanoma Evaluated after Starting Hu14.18-IL2

Author

Paul M. Sondel, Javed Khan, Mark R. Albertini, KyungMann Kim, Renae Quale, Zachary S. Morris, Amy K. Erbe, Cindy Zuleger, Jacquelyn A. Hank, Viharkumar Patel, Young K. Song, Vineela Gangalapudi, Berkley E. Gryder, Sivasish Sindiri, Jun S. Wei, Erik A. Ranheim, Igor B. Kuznetsov, and Richard K. Yang

Abstract

Purpose:We analyzed whole transcriptome sequencing in tumors from 23 patients with stage III or IV melanoma from a pilot trial of the anti-GD2 immunocytokine, hu14.18-IL2, to identify predictive immune and/or tumor biomarkers in patients with melanoma at high risk for recurrence.Experimental Design:Patients were randomly assigned to receive the first of three monthly courses of hu14.18-IL2 immunotherapy either before (Group A) or after (Group B) complete surgical resection of all known diseases. Tumors were evaluated by histology and whole transcriptome sequencing.Results:Tumor-infiltrating lymphocyte (TIL) levels directly associated with relapse-free survival (RFS) and overall survival (OS) in resected tumors from Group A, where early responses to the immunotherapy agent could be assessed. TIL levels directly associated with a previously reported immune signature, which associated with RFS and OS, particularly in Group A tumors. In Group A tumors, there were decreased cell-cycling gene RNA transcripts, but increased RNA transcripts for repair and growth genes. We found that outcome (RFS and OS) was directly associated with several immune signatures and immune-related RNA transcripts and inversely associated with several tumor growth–associated transcripts, particularly in Group A tumors. Most of these associations were not seen in Group B tumors.Conclusions:We interpret these data to signify that both immunologic and tumoral cell processes, as measured by RNA-sequencing analyses detected shortly after initiation of hu14.18-IL2 therapy, are associated with long-term survival and could potentially be used as prognostic biomarkers in tumor resection specimens obtained after initiating neoadjuvant immunotherapy.

Published
2023

16. Supplemental Figure SF-02 from Outcome-Related Signatures Identified by Whole Transcriptome Sequencing of Resectable Stage III/IV Melanoma Evaluated after Starting Hu14.18-IL2

Author

Paul M. Sondel, Javed Khan, Mark R. Albertini, KyungMann Kim, Renae Quale, Zachary S. Morris, Amy K. Erbe, Cindy Zuleger, Jacquelyn A. Hank, Viharkumar Patel, Young K. Song, Vineela Gangalapudi, Berkley E. Gryder, Sivasish Sindiri, Jun S. Wei, Erik A. Ranheim, Igor B. Kuznetsov, and Richard K. Yang

Abstract

Gene Signatures Prognosticating Survival after IC Treatment

Published
2023

17. Supplemental Figure SF-03 from Outcome-Related Signatures Identified by Whole Transcriptome Sequencing of Resectable Stage III/IV Melanoma Evaluated after Starting Hu14.18-IL2

Author

Paul M. Sondel, Javed Khan, Mark R. Albertini, KyungMann Kim, Renae Quale, Zachary S. Morris, Amy K. Erbe, Cindy Zuleger, Jacquelyn A. Hank, Viharkumar Patel, Young K. Song, Vineela Gangalapudi, Berkley E. Gryder, Sivasish Sindiri, Jun S. Wei, Erik A. Ranheim, Igor B. Kuznetsov, and Richard K. Yang

Abstract

Hu14.18-IL2 Treatment Improves Direct Positive Correlations between Myeloid and Lymphoid Cells as indicated by ssGSEA Signatures

Published
2023

18. Supplemental Figure SF-14 from Outcome-Related Signatures Identified by Whole Transcriptome Sequencing of Resectable Stage III/IV Melanoma Evaluated after Starting Hu14.18-IL2

Author

Paul M. Sondel, Javed Khan, Mark R. Albertini, KyungMann Kim, Renae Quale, Zachary S. Morris, Amy K. Erbe, Cindy Zuleger, Jacquelyn A. Hank, Viharkumar Patel, Young K. Song, Vineela Gangalapudi, Berkley E. Gryder, Sivasish Sindiri, Jun S. Wei, Erik A. Ranheim, Igor B. Kuznetsov, and Richard K. Yang

Abstract

Compared to Treatment Naïve Tumors (Group B and 2 untreated patients), IC treated Tumors (Group A) Demonstrate Increased Amounts of Growth Factor Expression, Oncogene and Immune Gene Expression, but Decreased Amounts of Melanoma Related Genes

Published
2023

19. Supplemental Figure SF-07 from Outcome-Related Signatures Identified by Whole Transcriptome Sequencing of Resectable Stage III/IV Melanoma Evaluated after Starting Hu14.18-IL2

Author

Paul M. Sondel, Javed Khan, Mark R. Albertini, KyungMann Kim, Renae Quale, Zachary S. Morris, Amy K. Erbe, Cindy Zuleger, Jacquelyn A. Hank, Viharkumar Patel, Young K. Song, Vineela Gangalapudi, Berkley E. Gryder, Sivasish Sindiri, Jun S. Wei, Erik A. Ranheim, Igor B. Kuznetsov, and Richard K. Yang

Abstract

Toll-Like Receptors Prognosticate Favorable Survival in Group A, But Not Group B

Published
2023

Catalog

Books, media, physical & digital resources
See catalog results